Secondary injury of the anterior cruciate ligament (ACL) is a common concern after anterior cruciate ligament (ACL) reconstruction, and identification of morphological risk factors is essential to prevent these injuries. We hypothesized that abnormal femoral trochlea morphology is associated with secondary ACL injuries after reconstruction. This study aimed to investigate the relationship between femoral trochlear morphology and secondary ACL injuries after reconstruction. A retrospective analysis was conducted on 20 patients who experienced secondary ACL injuries after reconstruction in our hospital between 2017 and 2022 (experimental group), and 40 patients were included in the control group. The following femoral trochlear characteristics were compared between the 2 groups: medial condylar height (MCH), trochlear sulcus height (TSH), lateral condylar height (LCH), trochlear sulcus depth (TSD), trochlear sulcus angle (TSA), medial trochlear inclination (MTI), and lateral trochlear inclination (LTI). The study found that patients in the secondary ACL injury after reconstruction group exhibited the following differences when compared to the control group: decreased MCH (56.33 ± 3.52 vs 59.93 ± 3.24, P value = .015), decreased TSD (4.89 ± 1.56 vs 6.98 ± 1.23, P value ˂ .001), decreased MTI (12.54 ± 6.57 vs 19.45 ± 6.35, P value ˂ .001), and increased TSA (145.23 ± 9.76 vs 139.25 ± 8.42, P value ˂ .001). This study demonstrated a significant correlation between abnormal femoral trochlear morphological characteristics and secondary ACL injuries after reconstruction. Decreased MCH, TSD, and MTI along with increased TSA are associated with a higher risk of secondary ACL injury. These data could thus help identify individuals susceptible to secondary ACL injuries after reconstruction.

Chronic inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis are known for a combination of food intolerance, decreased oral intake, and malabsorption which all predispose patients to malnutrition and suboptimal dietary intake. The present study was conducted to 1) examine self-reported food intolerances and dietary supplement use 2) assess nutritional intake 3) assess the nutritional status and screen for malnutrition among patients with chronic inflammatory bowel disease (CIBD).

Diabetes mellitus (DM) is a common chronic endocrine and metabolic disease, and its complications can involve multiple organs and seriously threaten human health. Double-stranded DNA (dsDNA) plays an important role in the autoimmune system; however, the correlation between dsDNA and DM has not been fully studied. This study recruited 388 diabetic patients and 2970 healthy controls to investigate the relationship between serum dsDNA and DM. The diagnosis of DM was based on the medical diagnostic and treatment standards for DM published by the American Diabetes Association (ADA). The study adhered to ethical principles and obtained informed consent from all participants. We measured serum dsDNA levels in both diabetic patients and healthy controls. The study examined differences in serum dsDNA levels among diabetic patients under various conditions, including different temperatures, ultraviolet (UV) light exposure, seasons, and clinical indicators. Additionally, quantitative PCR was used to assess the expression of dsDNA receptors, single-stranded RNA (ssRNA) receptors, absent in melanoma factor 2 (AIM2)-related inflammatory factors, and Type I interferon (INF) in the peripheral blood of patients and control groups. Peripheral blood serum dsDNA levels were elevated in diabetic patients compared to controls (mean values 1.09 and 0.97 ng/ml, respectively, < 0.001). We also found that the gene expression levels of dsDNA receptor, ssRNA receptor, AIM2-related inflammatory factors, and Type I IFN in diabetic patients were upregulated. And serum dsDNA levels correlated with clinical indicators. We have confirmed that DM is closely associated with serum dsDNA levels. Therefore, dsDNA detection shows promise as a novel approach for evaluating DM progression, offering new insights for the future diagnosis and treatment of DM.